FR22C1034I1 - FIXED DRUG RATIOS FOR THE TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS - Google Patents

FIXED DRUG RATIOS FOR THE TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS

Info

Publication number
FR22C1034I1
FR22C1034I1 FR22C1034C FR22C1034C FR22C1034I1 FR 22C1034 I1 FR22C1034 I1 FR 22C1034I1 FR 22C1034 C FR22C1034 C FR 22C1034C FR 22C1034 C FR22C1034 C FR 22C1034C FR 22C1034 I1 FR22C1034 I1 FR 22C1034I1
Authority
FR
France
Prior art keywords
treatment
proliferative disorders
hematopoietic cancers
fixed drug
drug ratios
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1034C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rotalec Ip Holdings LLC
Original Assignee
Rotalec Ip Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1034(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rotalec Ip Holdings LLC filed Critical Rotalec Ip Holdings LLC
Publication of FR22C1034I1 publication Critical patent/FR22C1034I1/en
Application granted granted Critical
Publication of FR22C1034I2 publication Critical patent/FR22C1034I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
FR22C1034C 2007-02-16 2022-07-05 FIXED DRUG RATIOS FOR THE TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS Active FR22C1034I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US96519607P 2007-08-17 2007-08-17
EP08730048.9A EP2120568B1 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
PCT/US2008/054168 WO2008101214A2 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Publications (2)

Publication Number Publication Date
FR22C1034I1 true FR22C1034I1 (en) 2022-09-09
FR22C1034I2 FR22C1034I2 (en) 2023-06-30

Family

ID=39690832

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1034C Active FR22C1034I2 (en) 2007-02-16 2022-07-05 FIXED DRUG RATIOS FOR THE TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS

Country Status (20)

Country Link
US (2) US8092828B2 (en)
EP (3) EP3300601B1 (en)
JP (1) JP5314600B2 (en)
KR (2) KR20150038752A (en)
CN (1) CN105998046A (en)
AU (1) AU2008216083B2 (en)
CA (1) CA2678332C (en)
CY (1) CY1119631T1 (en)
DK (2) DK2120568T3 (en)
ES (2) ES2909903T3 (en)
FR (1) FR22C1034I2 (en)
HK (1) HK1253378A1 (en)
HR (1) HRP20220428T3 (en)
HU (2) HUE058334T2 (en)
NL (1) NL301185I2 (en)
NO (1) NO2120568T3 (en)
PL (2) PL2120568T3 (en)
PT (2) PT3300601T (en)
SI (1) SI3300601T1 (en)
WO (1) WO2008101214A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
KR102284689B1 (en) * 2011-10-21 2021-08-02 셀라토 파마슈티칼즈, 인코포레이티드 Lyophilized liposomes
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3373919A4 (en) 2015-11-11 2019-06-19 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019023873A1 (en) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 Nano-lipid microparticle composition and pharmaceutical composition for treating hematopoietic system proliferative diseases
MX2021003527A (en) * 2018-09-25 2021-05-27 Celator Pharmaceuticals Inc Low-intensity treatment of hematological disorders.
CN113473980A (en) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 Gamma-hydroxybutyrate compositions with improved pharmacokinetics in fed state
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
ZA200503653B (en) * 2002-11-06 2006-08-30 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
BR0215935A (en) * 2002-11-06 2005-08-09 Wyeth Corp Combination therapy for treatment of acute leukemia and myelodysplastic syndrome
PT1744764E (en) 2004-04-22 2012-08-30 Celator Pharmaceuticals Inc Liposomal formulations of anthracycline agents and cytidine analogs
SE0402025D0 (en) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
WO2007076117A2 (en) 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof

Also Published As

Publication number Publication date
EP2120568A2 (en) 2009-11-25
EP3300601A1 (en) 2018-04-04
AU2008216083A1 (en) 2008-08-21
CA2678332A1 (en) 2008-08-21
PT3300601T (en) 2022-04-21
EP2120568A4 (en) 2010-04-21
JP2010519224A (en) 2010-06-03
US8092828B2 (en) 2012-01-10
HUE058334T2 (en) 2022-07-28
HK1253378A1 (en) 2019-06-14
FR22C1034I2 (en) 2023-06-30
AU2008216083B2 (en) 2014-02-06
CY1119631T1 (en) 2018-04-04
AU2008216083A2 (en) 2009-09-24
ES2650167T3 (en) 2018-01-17
HRP20220428T3 (en) 2022-05-27
HUS2200032I1 (en) 2022-07-28
WO2008101214A3 (en) 2008-11-20
NO2120568T3 (en) 2018-04-14
PL3300601T3 (en) 2022-05-02
KR20100014441A (en) 2010-02-10
JP5314600B2 (en) 2013-10-16
DK3300601T3 (en) 2022-03-21
ES2909903T3 (en) 2022-05-10
CA2678332C (en) 2015-06-02
US20080199515A1 (en) 2008-08-21
EP2120568B1 (en) 2017-11-15
EP4046640A1 (en) 2022-08-24
DK2120568T3 (en) 2017-12-11
EP3300601B1 (en) 2022-01-12
US20100303895A1 (en) 2010-12-02
PL2120568T3 (en) 2018-03-30
CN105998046A (en) 2016-10-12
SI3300601T1 (en) 2022-05-31
KR20150038752A (en) 2015-04-08
NL301185I2 (en) 2022-07-21
WO2008101214A2 (en) 2008-08-21
PT2120568T (en) 2017-12-04

Similar Documents

Publication Publication Date Title
FR22C1034I2 (en) FIXED DRUG RATIOS FOR THE TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS
FR2925339B1 (en) DRUG FOR THE TREATMENT OF PANCREATIC CANCER
FR2948016B1 (en) ORTHESIS FOR THE TREATMENT OF RHIZARTHROSIS
HK1163119A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4
FR2929946B1 (en) NOVEL ANTI-CD151 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER
FR2907011B1 (en) USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP2205236A4 (en) Novel agents for treatment of ailments and dysfunctions
FR2915102B1 (en) USE OF ANTI-CXCR4 ANTIBODY FOR THE TREATMENT OF CANCER
FR2948687B1 (en) USE OF MICROARN FOR THE TREATMENT OF CHRONIC RESPIRATORY DISEASES
IL217839A (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
MA44700A (en) COMBINATION OF ANTI-IL-10 ANTIBODY AND CPG-C OLIGONUCLEOTIDE FOR THE TREATMENT OF CANCER
FR2917947B1 (en) PHYTOSANITARY COMPOSITION FOR THE PREVENTIVE AND CURATIVE TREATMENT OF MILDIOU
FR2902320B1 (en) USE OF BUTYLATED HYDROXYANISOLE FOR THE TREATMENT OF CANITIA
FR2910324B1 (en) NEW MEDICINE FOR THE TREATMENT OF GASTRIC CANCER
FR2910813B1 (en) NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
FR2924593B1 (en) BONE PLATE FOR THE TREATMENT OF THE LOWER END OF THE CUBITUS
SI2344166T1 (en) Pharmaceutical composition for the treatment of gastrointestinal irritation disorders
FR2916345B1 (en) DEVICE FOR THE TREATMENT OF THE REAGONMENT OF THE EYE
FR2937550B1 (en) USE OF CITRULLINE FOR THE TREATMENT AND PREVENTION OF ISCHEMIA-REPERFUSION SYNDROME
FR2953412B1 (en) MEDICAMENT FOR THE TREATMENT OF GASTROINTESTINAL ULCERS
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
FR2921061B1 (en) INDOLONE DERIVATIVES FOR THE TREATMENT OF MALARIA
FR2902321B1 (en) USE OF CURCUMIN FOR THE TREATMENT OF CANITIA